menu
    • menu
    [{"orgOrder":0,"company":"Hemispherian","sponsor":"EIC fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"GLIX1","moa":"TET2","graph1":"Oncology","graph2":"Preclinical","graph3":"Hemispherian","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hemispherian \/ EIC fund","highestDevelopmentStatusID":"4","companyTruncated":"Hemispherian \/ EIC fund"},{"orgOrder":0,"company":"Hemispherian","sponsor":"Meneldor","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series A Financing","leadProduct":"GLIX1","moa":"TET2","graph1":"Oncology","graph2":"Preclinical","graph3":"Hemispherian","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hemispherian \/ Meneldor","highestDevelopmentStatusID":"4","companyTruncated":"Hemispherian \/ Meneldor"},{"orgOrder":0,"company":"Hemispherian","sponsor":"Research Council of Norway","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"GLIX5","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Hemispherian","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hemispherian \/ Research Council of Norway","highestDevelopmentStatusID":"4","companyTruncated":"Hemispherian \/ Research Council of Norway"},{"orgOrder":0,"company":"Hemispherian","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"GLIX1","moa":"TET2","graph1":"Oncology","graph2":"Preclinical","graph3":"Hemispherian","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hemispherian \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hemispherian \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Hemispherian

    Menu

    Hemispherian

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Hemispherian

                            U.S.A arrow
                            CRS
                            Not Confirmed

                            Hemispherian

                            U.S.A arrow
                            CRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GLIX1

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Hemispherian Gets EU Orphan Drug Status for GLIX1 in Glioma

                            Details : GLIX1 is a small molecule in preclinical studies for the treatment of glioblastoma. It is supposed to act on TET2 to increase genomic 5-hydroxymethylcytosine levels.

                            Product Name : GLIX1

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            June 06, 2025

                            Lead Product(s) : GLIX1

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Hemispherian

                            U.S.A arrow
                            CRS
                            Not Confirmed

                            Hemispherian

                            U.S.A arrow
                            CRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GLIX5

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Research Council of Norway

                            Deal Size : $1.5 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Hemispherian Awarded NOK 16M Grant from the Research Council of Norway

                            Details : The funding aims to support the Hemispherian in clinically advancing its investigational product GLIX5, a TET2 modulator, which is being evaluated in the preclinical studies for the treatment of platinum-resistant ovarian cancers.

                            Product Name : GLIX5

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            December 19, 2023

                            Lead Product(s) : GLIX5

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Research Council of Norway

                            Deal Size : $1.5 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Hemispherian

                            U.S.A arrow
                            CRS
                            Not Confirmed

                            Hemispherian

                            U.S.A arrow
                            CRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GLIX1

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Meneldor

                            Deal Size : $2.9 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Hemispherian Raises the First Tranche of A Series A To Fund the Development of Its Novel Cancer Therapeutics

                            Details : The proceeds will support the company's drug development activities, expand its preclinical pipeline and support preclinical development of GLIX1 and GLIX5, the company's lead assets.

                            Product Name : GLIX1

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            November 24, 2022

                            Lead Product(s) : GLIX1

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Meneldor

                            Deal Size : $2.9 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Hemispherian

                            U.S.A arrow
                            CRS
                            Not Confirmed

                            Hemispherian

                            U.S.A arrow
                            CRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GLIX1

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : EIC fund

                            Deal Size : $9.9 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Hemispherian Secures EUR 10M in Financing from the European Innovation Council (EIC) Accelerator Program

                            Details : The financing will support the company's lead compound, GLIX1, is in late-stage preclinical development for the treatment of glioblastoma, a deadly cancer of the central nervous system and the leading cause of death by disease in children.

                            Product Name : GLIX1

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            October 19, 2022

                            Lead Product(s) : GLIX1

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : EIC fund

                            Deal Size : $9.9 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth